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Abstract
Postpartum contraception is important to prevent unintended pregnancies. Assisting women in achieving
recommended inter-pregnancy intervals is a significant maternal-child health concern. Short inter-pregnancy
intervals are associated with negative perinatal, neonatal, infant, and maternal health outcomes. More than 30% of
women experience inter-pregnancy intervals of less than 18 months in the United States. Provision of any
contraceptive method after giving birth is associated with improved inter-pregnancy intervals. However, concerns
about the impact of hormonal contraceptives on breastfeeding and infant health have limited recommendations
for such methods and have led to discrepant recommendations by organizations such as the World Health
Organization and the U.S. Centers for Disease Control and Prevention. In this review, we discuss current
recommendations for the use of hormonal contraception in the postpartum period. We also discuss details of the
lactational amenorrhea method and effects of hormonal contraception on breastfeeding. Given the paucity of high
quality evidence on the impact on hormonal contraception on breastfeeding outcomes, and the strong evidence
for improved health outcomes with achievement of recommended birth spacing intervals, the real risk of
unintended pregnancy and its consequences must not be neglected for fear of theoretical neonatal risks. Women
should establish desired hormonal contraception before the risk of pregnancy resumes. With optimization of
postpartum contraception provision, we will step closer toward a healthcare system with fewer unintended
pregnancies and improved birth outcomes.
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Background
Postpartum contraception is important to prevent unin-
tended pregnancies and short intervals between preg-
nancies. The appropriate method and timing of
contraception initiation following a birth, miscarriage or
pregnancy termination depends on multiple factors such
as a patient’s personal preferences, medical history, risk
for pregnancy, breastfeeding preferences, and access to
contraceptive services. The most important role of post-
partum contraception is to help a woman achieve the
desired interval before the next pregnancy in order to
optimize her health and that of her young children. The-
oretical concerns regarding the impact of contraception
on breastfeeding must be appropriately weighed against
well-supported impacts on inter-pregnancy intervals and
the woman’s informed decisions regarding her repro-
ductive health.
Inter-pregnancy interval and perinatal outcomes
Assisting women in achieving recommended inter-
pregnancy intervals (IPIs), defined as the time interval
between a live birth and the beginning of the next preg-
nancy, is a significant maternal-child health concern.
Short IPIs are associated with negative perinatal, neo-
natal, infant, and maternal health outcomes. The con-
cept of an ideal inter-pregnancy interval emerged from a
report published by World Health Organization (WHO)
in 2005. Based on the best available evidence at that
time, the experts reached a consensus of 24 months as
the IPI. This interval was consistent with the joint WHO
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and United Nations Children’s Emergency Fund
(UNICEF) recommendation that women breastfeed for
at least 2 years [1].
Recommendations from the WHO report, “Effect of
Interpregnancy Interval on Adverse Perinatal Outcomes,”
were evaluated using the Perinatal Information System
Database of the Latin American Center for Perinatology
and Human Development from 1985 to 2004. Compared
to infants with IPIs of 18–23 months, those born to
women with intervals shorter than 6 months had an
increased risk of many adverse neonatal and perinatal
outcomes [2]. A systematic review by Conde-Agudelo et
al. that included 77 studies conducted in countries across
six continents analyzed the association of IPIs with out-
comes such as preterm birth, low birth weight, small size
for gestational age (SGA) at birth, fetal death, and early
neonatal death. For IPIs shorter than 6 months, there were
significantly increased risks for preterm birth (Odds Ratio
= 1.40), SGA (Odds Ratio =1.26), and low birth weight
(Odds Ratio = 1.61). Intervals of 6 to 17 months were also
associated with a significantly greater risk for these three
adverse perinatal outcomes. Additionally, among women
with previous low-transverse caesarean sections who
underwent trials of labor, there was noted to be increased
risk of uterine rupture with IPIs less than 16 months [3].
Another recent study analyzing all live births between 1991
and 2010 in California concluded that women with IPIs of
less than 1 year following live birth were at increased risk
for preterm birth [4]. No conclusions on the impact of IPI
on maternal mortality and morbidity were able to be drawn
in the WHO’s report due to limited available data [1].
Unfortunately, data from the 2015 National Vital
Statistics Report and the National Survey of Family
Growth demonstrate that in the United States 30% of
women experience IPIs of less than 18 months. Short IPIs
in the U.S. are inversely associated with maternal age, with
more than two thirds (67%) of teenagers between ages
15–19 experiencing IPIs of less than 18 months [5].
Postpartum endocrine changes
To understand the timing and mechanisms by which
women resume risk of pregnancy following delivery, it is
important to review the cascade of endocrine changes
that take place after parturition. Immediately following
delivery, the inhibitory effect of the estrogen and proges-
terone levels of pregnancy decreases and the pulsatile
activity of the pituitary follicular stimulating hormone
(FSH) and luteinizing hormone (LH) resumes [6]. In
non-lactating women, studies evaluating urinary pregna-
nediol levels have reported a mean first ovulation
ranging from 45 to 94 days postpartum, with the earliest
ovulation reported 25 days after delivery [7, 8]. Conse-
quently, women are assumed to be protected from preg-
nancy for 4 weeks following delivery. Similarly, studies
looking at ovulation after abortion suggest that most
women ovulate before resuming menses, with mean time
to ovulation of 22 days [9]. Lactation extends the period
of postpartum infertility. Nerve impulses arising from
the nipple and areola due to infant suckling release pro-
lactin from the hypothalamus. This, in turn, suppresses
the pulsatile release of gonadotropin-releasing hormone
(GnRH) by the hypothalamus, likely by increasing beta-
endorphin production. The pulsatile secretion of GnRH
is necessary to stimulate the cells in anterior pituitary to
produce FSH and LH needed for ovulation. Thus contin-
ued suckling and lactation provide protection from preg-
nancy [10].
Lactational amenorrhea method
The lactational amenorrhea method (LAM) is the specific
name given to use of breastfeeding as a dedicated method
of contraception. For breastfeeding to serve as an effective
method of contraception, the woman must be exclusively
or nearly exclusively breastfeeding (at least 85% of infant
feeding coming from breastfeeding), be within the first
6 months following delivery, and remain amenorrheic.
Some experts additionally believe that milk expression by
hand or pump does not retain the same fertility-inhibiting
effect as infant nursing [11]. Clinical studies of the contra-
ceptive effect of LAM have demonstrated cumulative 6-
month life-table perfect-use pregnancy rates of 0.5 – 1.5%
among women who relied solely on LAM. A Cochrane re-
view published in 2015 estimated the typical use failure
rate of LAM to be 0.45 – 7.5% [12–15].
Although LAM is a highly effective temporary method
of contraception, rates of the exclusive breastfeeding
required for its effectiveness are low in the United
States. Data from the National Immunization Survey
describes an 80% incidence of breastfeeding initiation,
declining to a 4 weeks postpartum exclusive breastfeed-
ing rate of 54%, which declines to 20% at 6 months [16].
According to this data, exclusive breastfeeding rates at
3 months were lower in non-white, unmarried women
with lower socio-economic status compared to non-
Hispanic white, well educated, married women [16].
Among the individual states, Montana had the highest
(60%) and Mississippi the lowest (21%) exclusive breast-
feeding rates at 3 months in 2013 [17].
Historically, women have also been assumed to experi-
ence protection from pregnancy during the traditionally
recommended 6-week period of pelvic rest following
delivery. While 6-weeks may have been historically
recommended to accommodate the expected time period
of uterine involution, and due to its concurrent timing
with the historically recommended 6-week postpartum
visit, no evidence supports any specific interval of post-
delivery abstinence. McDonald et al. [18] analyzed a pro-
spective cohort of approximately 1500 nulliparous women
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to investigate the timing of resumption of vaginal sex after
childbirth and noted that 41% of women admitted to re-
suming intercourse by 6 weeks, while 65 and 78% en-
dorsed vaginal sex by 8 and 12 weeks postpartum,
respectively. Spontaneous vaginal birth with an episiotomy
or laceration, forceps- or vacuum-assisted vaginal birth,
cesarean section, and breastfeeding are negatively associ-
ated with resumption of intercourse following delivery,
while young age (<25 years) and living with a partner are
associated with earlier resumption of intercourse [18].
Contraception provision postpartum
Given that women resume risk for pregnancy from
4 weeks to 6 months postpartum, effective contraceptive
methods must be available to assist women in reaching
recommended IPIs. Figure 1 demonstrates currently
available contraceptive methods in the U.S. and their as-
sociated effectiveness in typical use. Provision of any
contraceptive method within 90 days of giving birth is
associated with improved IPIs [19]. However, use of
long-acting reversible contraception methods (LARC)
such as intrauterine devices (IUDs) and the subcutane-
ous contraceptive implant, both with effectiveness that is
generally not reduced by user error, have been shown to
substantially improve IPIs compared to other methods.
More specifically, women using LARC methods after de-
livery have 3.89 times the likelihood of reaching recom-
mended birth spacing intervals compared to women
using condoms only, while women using user-dependent
hormonal methods (pill, patch, vaginal ring and injection)
have 1.89 times the likelihood of achieving recommended
spacing compared to barrier method users [19, 20].
Fig. 1 Effectiveness of Family Planning Methods (Adapted from Centers for Disease Control and Prevention)
Sridhar and Salcedo Maternal Health, Neonatology, and Perinatology  (2017) 3:1 Page 3 of 10
Recommendations by the World Health Organization and
Centers for Disease Control and Prevention
Despite evidence that early initiation of postpartum
contraception increases IPIs, concerns about the impact
of hormonal contraceptives on breastfeeding and infant
health have limited recommendations for such methods
and have lead to discrepant recommendations by organi-
zations such as the World Health Organization (WHO)
and the U.S. Centers for Disease Control and Prevention
(CDC). While both the WHO and CDC generally agree
that the initiation of estrogen-containing methods
should be delayed for 3–6 weeks postpartum (depending
on a woman’s medical risk factors) until the risk of ven-
ous thromboembolism (VTE) decreases to approxi-
mately the non-pregnant baseline, the WHO has issued
more conservative recommendations than the CDC re-
garding use of both estrogen-containing and progestin-
only methods by breastfeeding women [21, 22].
In the WHOMedical Eligibility Criteria for Contraceptive
Use (MEC), Fifth Edition [23] estrogen-containing contra-
ceptives (including combined oral contraceptives, the patch,
and the vaginal ring) are considered to pose unacceptable
health risks (Category 4) when used by breastfeeding
women within the first 6 postpartum weeks. These
methods are considered by the WHO to have theoretical or
proven risks that usually outweigh their advantages (Cat-
egory 3) until breastfeeding women are at least 6 months
postpartum. In contrast, in the U.S. Centers for Dis-
ease Control and Prevention Medical Eligibility Cri-
teria for Contraceptive Use (CDC MEC), the
advantages of using such estrogen-containing methods
are stated to generally outweigh the theoretical or
proven risks (Category 2) for women without compli-
cating medical conditions starting 6 weeks after deliv-
ery [21] (Table 1).
In the following sections we provide a detailed review
of the impact of each hormonal contraceptive method
on breastfeeding outcomes.
a) Combined oral contraceptives
A CDC review of combined oral contraceptives from
2015 included 15 articles from 13 studies evaluating the
impact of estrogen-containing oral contraceptive pills on
breastfeeding and associated infant outcomes. Unfortu-
nately, applicable studies were noted to be of only poor
to fair methodological quality and many were from earl-
ier decades when the estrogen-content of combined oral
contraceptives was substantially higher than in modern
pills [24]. In this review, no studies found significant im-
pact on infant weight gain when combined oral contra-
ceptives (COCs) were initiated at 6 weeks or later
postpartum, and none found negative impact on other
infant health outcomes regardless of the timing of COC
initiation [24]. However, the results of studies examining
the impact of COCs on breastfeeding performance were
inconsistent [24]. A study by the WHO in 1984 assigned
women to a COC containing 30 micrograms of ethinyl
estradiol and 150 micrograms of levonorgestrel or a
progestin-only pill containing 75 micrograms of norges-
trel, started after 6 weeks postpartum. Breast milk
volume was quantified following pump expression. Mean
breast milk volume was lower in the COC group at 9, 16
Table 1 Medical Eligibility Criteria [CDC/WHO]
Method <10 min <48 h <21 days 21 to <30 days 30-42 days 42 days-6 months >6 months
Breastfeeding Women Category [CDC/WHO]
Combined hormonal contraceptives 4/4 4/4 4/4 3/4 2a/4 2/3c 2/2
Progestin-only pills 2/2 2/2 2/2 2/2 1/2 1/1 1/1
DMPA 2/3 2/3 2/3 2/3 1/3 1/1 1/1
Etonogestrel implant 2/2 2/2 2/2 2/2 1/2 1/1 1/1
Levonorgestrel intrauterine device 2/2 2/2 2/3 2b/3b 1b/1b 1/1 1/1
Copper intrauterine device 1/1 2/1 2/3 2b/3b 1b/1b 1/1 1/1
Nonbreastfeeding Women Category [CDC/WHO]
Combined hormonal contraceptives 4/3d 4/3d 4/3d 2a/2a 2a/2a 1/1 1/1
Progestin-only pills 1/1 1/1 1/1 1/1 1/1 1/1 1/1
DMPA 1/1 1/1 1/1 1/1 1/1 1/1 1/1
Etonogestrel implant 1/1 1/1 1/1 1/1 1/1 1/1 1/1
Levonorgestrel intrauterine device 1/1 2/1 2/3 2b/3b 1b/1b 1/1 1/1
Copper intrauterine device 1/1 2/1 2/3 2b/3b 1b/1b 1/1 1/1
a CDC & WHO Category 3 for women with other risk factors for VTE: 35 years old or older, previous VTE, thrombophilia, immobility, peripartum transfusion,
peripartum cardiomyopathy, obesity, peripartum hemorrhage, cesarean delivery, preeclampsia, or smoking
b Refers to 28 days for intrauterine device insertion timing
c Refers to women who are primarily breastfeeding
d WHO Category 4 for women with other risk factors for VTE
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and 24 weeks by 18–25 mL. However, no differences
were noted between groups on use of supplemental
infant nutrition [25]. In 2012, Espey et al. performed a
randomized controlled trial of breastfeeding women
following term delivery who desired to initiate oral
contraception. At two weeks postpartum women
initiated either a combined pill of 35 mcg ethinyl estra-
diol and 1 mg norethindrone (n = 64) or a progestin-
only pill (POP) containing 35 micrograms of norethin-
drone (n = 63) [26]. There was no significant difference
between the COC and POP groups in the primary out-
come of breastfeeding continuation over the 6 months
of follow-up, nor were there differences found in infant
growth parameters, satisfaction with breastfeeding or
oral contraceptive use, perception of milk supply ad-
equacy, formula supplementation, or reasons cited for
discontinuing breastfeeding or oral contraceptive pills
[26]. Given that in non-breastfeeding women without
contraindications to estrogen, combined oral contracep-
tives have been found to have better efficacy, higher con-
tinuation rates, and fewer side effects than POPs, and
that 35 micrograms is the highest estrogen content in
commonly used COCs, the authors conclude that it is
reassuring that combined pills do not have a major im-
pact on breastfeeding continuation or infant growth and
a larger equivalency study should be performed to clarify
the clinical impact of COCs on lactation [26]. No ran-
domized controlled trials are available that evaluate the
other estrogen-containing contraceptives available in the
U.S., the contraceptive patch and vaginal ring, which
have different hormonal content and absorption profiles
than combined oral contraceptive pills [25].
b) Progestin only contraceptives
In contrast to estrogen-containing contraceptives, the
WHO considers the benefits of progestin-only oral con-
traceptives and the progestin-containing contraceptive im-
plant to generally outweigh risks of these methods during
the first 6 postpartum weeks for breastfeeding women
(Category 2), but recommends that the contraceptive in-
jection (depot medroxyprogesterone acetate [DMPA] in
the U.S.) be initiated no sooner than 6 weeks postpartum
[23]. In contrast, the CDC considers the benefits of all
progestin-only systemic methods to outweigh potential
risks during the first 30 days postpartum for breastfeeding
women (Category 2), and states that all such methods may
be used without restriction (Category 1) 30 days following
delivery [21].
While the WHO acknowledges that available evidence
does not support a negative effect of progestin-only con-
traceptives on breastfeeding performance, and has gen-
erally demonstrated no negative impacts on infant
growth or development, concern over lack of evidence
on potential longer-term pediatric impacts have led to
conservative recommendations for hormonal contracep-
tive use, particularly for contraceptive injections during
the early postpartum period [23]. Animal data has sug-
gested some effect of progesterone on the developing
brain, but whether such effects are present in humans,
and of what potential consequences, are unclear [23, 27].
Although limited comparative studies have not noted a
difference in breastfeeding or infant outcomes with ex-
posure to progestin-injections compared to other
progestin-only methods, the higher maternal systemic
hormone levels attained with progestin-injections (com-
pared to other systemic progestin-only methods) have
led the WHO Guideline Development Group to be con-
cerned about infant hormone exposure during use of
these methods, particularly in the first 6 weeks [23].
Additionally, given the paucity of high quality evidence
in this area, WHO and CDC expert opinion may under-
standably differ based on issues such as the difference in
exclusive breastfeeding rates between U.S. women and
those in less developed parts of the world and the avail-
ability of safe alternatives to breast milk for infant and
early childhood nutrition.
While the steroids progesterone and nestorone are or-
ally inactive, progestin-containing contraceptives currently
used in the United States contain orally active progestins
[28]. The amount of progestin transferred to an infant
through breast milk by hormonal contraceptive users is
variable. For contraceptive implant users, the mean con-
centration of etonogestrel in breast milk ranges from 405
to 548 pmol/L, approximately one-half the maternal
plasma concentration, which results in transferring of ap-
proximately 75–120 nanograms of hormone per day to
the fully breastfed infant [28, 29]. This daily progestin dose
is similar to the range estimated for progestin-only pills,
which is approximately twice that of levonorgestrel-
releasing IUDs. It is significantly lower than that received
by infants whose mothers use progestin injectables, which
is in the range of 1–13 micrograms, approximately 88% of
the serum concentration [28, 30–32].
The issue of infant exposure to exogenous hormones
is further complicated by the fact that newborns are ini-
tially unable to either absorb or metabolize exogenous
hormones, followed by an ability to metabolize more
effectively than absorb, then an ability to do both suc-
cessfully by about 24 weeks of gestation [33]. For women
using levonorgestrel-releasing IUDs, compared to non-
hormonal IUDs, no differences were noted in infants’
serum electrolytes, protein, creatinine, iron, cholesterol,
or liver enzyme levels [31]. Similarly, no differences in
the biochemical markers of FSH, LH, testosterone, or
immunoglobin differences were noted between male in-
fants of progestin-only pill users or users of a progestin-
implant compared to non-hormonal contraceptive users
[34, 35].
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An updated review on progestin-only contraceptives
and breastfeeding by Phillips et al. in 2015 noted that 11
non-randomized trials and observational studies found ei-
ther no effect or a positive effect on breastfeeding out-
comes with use of progestin-injectables initiated within
the first 6 weeks postpartum [36] Similarly, eight observa-
tional studies on progestin-only pills and breastfeeding
found either no differences or improved breastfeeding
outcomes when pills were initiated within 6 weeks post-
partum [36]. A randomized controlled trial noted no dif-
ference in infant weight gain at 14 days compared to
infants not exposed to hormonal contraception [37, 38].
Similarly, in studies examining infant growth effects when
progestin-only methods are initiated after 6 weeks post-
partum, most have noted no differences, although small
differences in both directions have been found [39].
In a study by Reinprayoon et al., women who initiated
an etonogestrel implant while fully breastfeeding were
found to have similar breast milk volume, composition,
rates of initiation and timing of supplemental feedings,
and infant growth characteristics as women who initiated
a non-hormonal IUD [29]. Similarly, for women using a
levonorgestrel-releasing IUD, compared to women using
non-hormonal IUDs, mean duration of breastfeeding was
found to be similar, although slightly fewer women were
still breastfeeding at 75 days in the levonorgestrel group.
No differences were noted in the growth, health, or devel-
opmental milestones measured [32].
In addition to infant hormone exposure during the first
6 weeks postpartum, some experts have expressed con-
cern that immediate postpartum initiation of hormonal
contraceptives prior to the natural postpartum decline of
progesterone may have greater impact on breastfeeding
performance than methods initiated even in the early
weeks postpartum. Most recently, a randomized trial by
Chen et al. comparing postplacental to delayed levonor-
gestrel IUD insertion at 6–8 weeks noted that women in
the delayed group were more likely to still be breastfeed-
ing at 6 months postpartum, although no differences in
breastfeeding initiation or continuation at 6–8 weeks or at
3 months was seen [40]. This difference persisted when
women who never breastfed were excluded and when only
primiparous women without previous breastfeeding ex-
perience were considered [40]. A biologic etiology for this
difference only seen at 6 months is difficult to ascertain
given the low systemic levels of levonorgestrel found in
levonorgestrel-IUD users and the fact that any impact of
exogenous hormones on breastfeeding would seem most
plausible at or surrounding breastfeeding initiation.
Such a negative impact of immediate hormonal LARC
placement on breastfeeding outcomes has not been
found in studies evaluating the etonogestrel contracep-
tive implant [41, 42]. For instance, a study comparing
initiation of the contraceptive implant within 3 days
postpartum, compared to 4–8 weeks postpartum, found
no significant difference between full or any breastfeed-
ing at any time point, breast milk creamatocrit, or a clin-
ically significant difference in time to lactogenesis [42].
Another study that used deuterium (an isotope of hydro-
gen that is used as a tracer) to compare milk intake be-
tween infants whose mothers had a Nexplanon placed
within 48 h of delivery to those using no contraceptive
method found no difference in milk intake at any time
within 6 weeks and no difference in newborn weight be-
tween groups during the follow-up period [43].
Data on the impact of DMPA administration before
postpartum discharge is mixed but generally reassuring.
While a study of Peruvian women noted that women
who initiated DMPA more than 72 h postpartum were
more likely than both women who initiated DMPA
within 72 h postpartum and those who didn’t initiate
DMPA postpartum to be exclusively breastfeeding at
3 months, DMPA use overall was associated with higher
exclusive breastfeeding rates at 3 months compared with
non-use [44]. The authors of this study postulated that
increased contact with healthcare providers by women
who initiated DMPA more than 72 h following delivery
may have provided additional opportunities for breast-
feeding support [44]. In contrast, a prospective non-
randomized trial comparing progestin-only contraceptive
administration before postpartum discharge with non-
hormonal methods found that women who initiated
DMPA before postpartum discharge saw no difference in
breastfeeding continuation rates at 2 weeks or 6 weeks,
and no difference in discontinuation due to perceived in-
adequate milk supply, despite the fact that women in the
DMPA group were less likely to breastfeed based on
their younger age and lower gravidity and parity [45].
Study authors concluded that women who choose hor-
monal methods are likely to be different in breastfeeding
likelihood than women who initiate non-hormonal
methods or no method [45]. Similarly, a retrospective
cohort study by Brownell et al. found no significant dif-
ference in breastfeeding cessation within 2 or 6 weeks
postpartum between women who initiated DMPA before
postpartum discharge (a mean of 37 h following deliv-
ery) and women who did not initiate DMPA, but did
note that the DMPA group was significantly less likely to
have a timed breastfeeding goal (such as planning to
breastfeed until a particular infant age or developmental
milestone) and to report social support for breastfeeding.
These findings support the idea that women who choose
to initiate hormonal contraception before postpartum
discharge may be different in important ways from
women who make other postpartum contraceptive
choices [46]. The American College of Obstetricians &
Gynecologists (ACOG) recognizes that clinical judgment
must weigh the need for contraception against the
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theoretical neonatal risks and endorses early initiation of
DMPA postpartum in indicated clinical situations, such
as a high risk of being lost to postpartum follow-up [47].
c) Emergency contraceptive pills
In addition to routine contraception, emergency contra-
ception is a promising component of a comprehensive
contraceptive strategy to reach recommended birth spa-
cing intervals. Emergency contraceptive pills (ECPs) are
pills taken as soon as possible, and within 120 h, after
unprotected or inadequately protected intercourse in
order to reduce the risk of pregnancy when a routine
contraceptive method was not used or was not used cor-
rectly. Two types of dedicated ECP products are avail-
able in the U.S. They are progestin-only ECPs comprised
of 1.5 mg levonorgestrel, and 30 mg of ulipristal acetate,
which is a progestin-receptor modulator. Both medica-
tions work by delaying or preventing ovulation and
neither has evidence for post-fertilization effects [48].
Ulipristal acetate has been found to be more efficacious
overall, and specifically for overweight and obese women
and women who require ECPs for intercourse occurring
close to ovulation [49, 50]. In both the WHO and CDC
MEC, levonorgestrel ECPs are classified as Category 1
for all users [21, 23]. However, the WHO MEC classifies
use of ulipristal acetate by breastfeeding women as
Category 2 and recommends that women avoid breast-
feeding for 1 week following use, discarding breast milk
during that time, based on the package labeling for UPA
which states that, “Use of ella® by breastfeeding women
is not recommended,” since it is “unknown if ulipristal
acetate is excreted in human milk [23, 51].” In contrast,
the CDC MEC classifies ulipristal acetate use by breast-
feeding women as Category 1, but recommends that
breast milk be expressed and discarded for 24 h follow-
ing use. Since there are no studies evaluating the impact
of ulipristal acetate exposure on infants [52], the recom-
mendation to discard breast milk for 24 h is based on
rapidly declining levels of ulipristal acetate and its me-
tabolite measured in breast milk during this time period.
Professional organizations such as the ACOG and the
American Academy of Pediatrics (AAP) recommend ad-
vance prescription of emergency contraceptive pills to
all reproductive aged women [53, 54]. In a randomized
trial of breastfeeding Egyptian women who planned to
use LAM and delay a next conception by at least 1 year,
women in the standard LAM counseling group were sig-
nificantly more likely than women in the levonorgestrel
ECP advanced provision group to experience pregnancy
within 6 months postpartum (of which 80% were un-
planned and/or undesired), despite similar rates of unpro-
tected intercourse after expiration of LAM criteria in both
groups [55]. Unfortunately, knowledge of emergency
contraception by postpartum women is low. In a study of
inner city postpartum women, only 36% had heard of
emergency contraception, only 19% could name or de-
scribe a method of emergency contraception, and only 7%
could identify correct timing of ECP use [56]. Of those
who were aware of emergency contraception, only 44%
thought it was safe, despite CDC MEC Category 1–2 clas-
sification, and 32% incorrectly believed that it served as an
abortifacient [56]. However, two-thirds of women in the
study stated that they would be willing to use emergency
contraception in the future [56].
System based barriers for postpartum contraception use
Despite the effectiveness of currently available contra-
ception, U.S. women seeking to establish postpartum
contraception currently face a myriad of systems bar-
riers. Of women who indicate a plan for postpartum
IUD placement, only 23–60% undergo insertion as
planned [57, 58]. Women are often denied inpatient
LARC placement due to the fact that reimbursement for
all delivery-related care is generally based on a global fee
that does not carve out the cost of LARC devices or in-
sertions [59, 60]. This reimbursement scheme severely
disincentivizes hospitals to supply and dispense LARC
devices, which typically have wholesale costs upwards of
$600 [59]. While Medicaid and most private insurance
plans have been able to separate out reimbursement for
sterilization during a delivery-related hospitalization,
currently only a small minority of states have been able
to address the issue for LARC devices, and primarily
only for Medicaid-covered patients [59, 60]. Interest-
ingly, this slow systems-based change takes place in a
setting in which substantial cost-savings to public pro-
grams facilitating inpatient LARC placement has been
demonstrated [60]. Further barriers are encountered by
women who receive delivery-related care in Catholic
hospitals, which currently represent one-sixth of all hos-
pital beds in the U.S., as these facilities do not permit
placement of LARC devices for the purpose of contra-
ception [59].
Additionally, postpartum women often receive incon-
sistent, and sometimes incorrect, information from vari-
ous members of the healthcare team regarding the safety
and impact of contraception on breastfeeding. For in-
stance, in a recent survey by Dunn et al., while 77% of
lactation consultants reported offering advice about
postpartum contraception and its impact on breastfeed-
ing, the vast majority stated that progestin-only methods
used in the first 21 days following delivery had theoret-
ical or proven risks that outweighed benefits or pre-
sented unacceptable health risks (equivalent to MEC
Category 3 or Category 4), which is inconsistent with
medical professional guidelines and the best available
evidence [61]. Specifically, 76.3% stated that progestin-
only pills ought to be avoided during this time period,
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while 90.1% stated the same for DMPA and 92.1% for
the etonogestrel implant [61]. The inconsistencies found
in this study are particularly concerning, given that
lactation consultants are generally considered the prem-
ier experts on breastfeeding on postpartum inpatient
units where many women are finalizing contraceptive
choices for initiation before discharge.
Conclusion
Regardless of age and intended family size, unintended
pregnancy can occur at any point in a woman’s reproduct-
ive life. As women spend the majority of their reproduct-
ive years attempting to avoid unintended pregnancy,
contraception counseling is an important aspect women’s
healthcare, especially for those who have recently experi-
enced pregnancy. There are very few non-hormonal
contraceptive options available in the United States, and
most are associated with high failure rates in typical use.
Healthcare providers must communicate with women
about the typical use failure rates of contraceptives and as-
sist patients in initiating the most effective method that
best fits their medical situation and preferences. Providers
must also be familiar with USMEC and US Selected
Practice Recommendations for Contraceptive Use in order
to initiate and manage post-pregnancy contraception
safely and appropriately [21]. Further, many women use
contraceptive methods for their non-contraceptive bene-
fits and may need to initiate or resume methods for such
purposes postpartum. The USMEC clarifies that recom-
mendations refer to the safety of contraceptive methods
when used for contraceptive purposes and do not apply to
the use of contraceptive methods for treatment of medical
conditions (as the eligibility criteria may differ in such cir-
cumstances) [21].
Women may wish to discuss contraception both pre-
natally and after hospital discharge. A multicenter ran-
domized controlled study evaluating antenatal
discussion of planned postpartum contraception failed
to demonstrate significant effect on contraceptive use or
subsequent pregnancy rates [62]. An evaluation of post-
partum contraception educational method by the
Cochrane database also failed to identify specific strat-
egies that work universally to improve awareness of
women in this regard. Thus, to date, research has not
reached a consensus on the optimal timing and method
to discuss postpartum contraception with patients [63].
Despite the paucity of high quality evidence of the im-
pact on hormonal contraception on breastfeeding out-
comes, and the strong evidence for improved health
outcomes with achievement of recommended birth spa-
cing intervals, some authors have gone as far as to sug-
gest that conducting a controlled trial to evaluate the
effects of timing of hormonal contraception initiation on
lactation would be unethical given the primacy of non-
hormonal methods in breastfeeding and the fact that
hormonal contraceptives could theoretically have nega-
tive impacts [64]. However, other authors have advo-
cated strongly that the real risk of unintended pregnancy
and its consequences must not be neglected for fear of
the theoretical neonatal risks, and that women should
establish desired hormonal contraception before the risk
of pregnancy resumes, which is generally 4 weeks fol-
lowing delivery unless criteria for the lactational amen-
orrhea method is met [65].
Women who desire a contraceptive method should
have it available as soon as possible. Advanced provision
of EC is recommended by professional societies and may
serve an important role postpartum. Systems barriers to
women’s ability to achieve recommended birth spacing
must be addressed. With optimization of postpartum
contraception provision, we will step closer toward a
healthcare system with fewer unintended pregnancies
and improved birth outcomes.
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